Client Result
Orrick Advises SFJ Pharmaceuticals on Acquisition of Bentracimab Assets from PhaseBio
January.18.2023
Orrick advised SFJ on its acquisition of assets related to the drug Bentracimab from PhaseBio.
January.18.2023
Orrick advised SFJ on its acquisition of assets related to the drug Bentracimab from PhaseBio.
September.19.2019
September.26.2017
August.31.2017